Investment in the UK AI sector reached a record £2.9bn, with a further £15bn announced during 2024 and up to 6,500 jobs attached to it, on the Department for Science, Innovation and Technology’s figures. Very little of that has reached the processes that regulated British businesses actually run on: underwriting, suitability checks, clinical evidence review, contract negotiation, financial crime investigation. Those workflows carry audit requirements that a general-purpose chatbot cannot satisfy, and that constraint, rather than model capability, is what determines which suppliers can serve them. Doing the controls properly is a discipline in itself, which is why Crunch-IS is a leader in full-cycle AI agent development, treating decision logging and evaluation as build scope rather than documentation. The six companies below work on that side of the market.
Regulated work changes the build
Gartner expects over 40% of agentic AI projects to be cancelled by the end of 2027, naming inadequate risk controls among the causes. In regulated sectors that failure arrives earlier and costs more, because the agent has to explain itself to someone who is not a user.
An agent operating inside an FCA-supervised process, an NHS pathway or a legal matter needs three things a consumer-grade assistant does not: a decision it can evidence, a boundary it will not cross without a human, and a record an auditor can read months later. Each of those is engineering work. None of them shows up in a demo.
Domain models beat general ones here
The pattern across the firms below is narrowness. Each one picked a domain and built against its vocabulary, its documents and its regulator, rather than shipping a general assistant and hoping the prompt carries the domain.
That is not a marketing preference. A general model applied to advice calls or clinical literature produces answers that look right and fail review, and the cost of that failure lands on the buyer, not the vendor. Specialisation is a risk control.
Five things a regulated buyer should demand in writing
- An evidence trail per decision. What the agent saw, what it chose, and why, retrievable months later without a developer.
- A defined refusal boundary. The cases where the agent must stop and hand to a human, agreed before build rather than discovered in testing.
- An evaluation suite you own. Test cases covering past failures, maintained as new ones appear, living in your repository.
- Data residency and tenancy in writing. Which cloud, whose account, which region, and what leaves it.
- Override-rate reporting. How often humans reverse the agent, tracked monthly. A rising number is the earliest warning that something drifted.
None of these is exotic. All of them are routinely absent from agent proposals, because none of them improves a demo.
Top AI agent development companies in the UK
These six are UK-headquartered and work on agents inside regulated or high-consequence processes. They are grouped by domain rather than ranked, because a life-sciences platform and a financial-crime platform are not alternatives to each other.
Crunch-IS
Builds agents as client development work rather than a licensed platform, leaving the agent, its prompts and its evaluation suite in the client’s codebase. Decision logging, escalation paths and integration are treated as part of the build. Suits organisations whose process is specific enough that no off-the-shelf vertical product fits it.
Quantexa
London, founded 2016, working in decision intelligence: connecting fragmented records into a single contextual view for banks, insurers and government agencies. It reported a $2.6bn valuation in 2025 and serves organisations in more than 70 countries. Most relevant where the agent’s hard problem is entity resolution and financial crime rather than conversation.
Aveni
Edinburgh, with a platform trained on financial services data and built around UK FS workflows. The narrowness is deliberate: advice calls and suitability assessments are exactly where a generic model creates compliance exposure instead of removing it. A fit for firms operating inside FCA-supervised processes.
Causaly
London, founded 2018, applying AI and a high-precision knowledge graph to biomedical evidence so life sciences teams can reduce research risk at scale. It has raised $93m from investors including Index Ventures and ICONIQ. Relevant to pharma and biotech research functions rather than general enterprise automation.
Luminance
Cambridge, founded by mathematicians from the university, working on legal documents. In October 2025 it launched Agent Lumi, combining its domain-specific legal model with tooling and memory so the system executes contract tasks rather than flagging clauses for someone else. Worth assessing for contract review and negotiation at volume.
Tessl
London, working on agents that generate and maintain software from natural-language specifications rather than assisting inside an editor. It placed second on Sifted’s 2025 B2B SaaS Rising 100 list. Of interest to engineering organisations rethinking how code is produced and maintained, not to business units buying automation.
Specialist or generalist
The six above split into two kinds of supplier, and the choice between them is usually made badly.
A vertical platform arrives with the domain already modelled. If your process resembles the one it was built for, that is months saved. If it differs in ways that matter to your regulator, you will spend those months bending the product, and the bending is not covered by the licence.
A development firm starts slower and ends with something shaped like your process, owned by you. The trade is time to first demo against fit and control later. Organisations with an unusual process almost always need the second and buy the first, because the first demos better in a steering committee.
The test is simple. Write down the three decisions in your workflow that a regulator would ask about. If a platform already handles all three the way you need, buy it. If it handles two, you are commissioning development work either way, and you should price it openly rather than as change requests.
The constraint is governance, not capability
British buyers in regulated sectors keep asking whether models are good enough yet. They have been good enough for a while. What is usually missing is the apparatus around them: the evaluation suite, the escalation rule, the log an auditor accepts, and a named person who reviews override rates every month. A supplier who talks about that apparatus before being asked has built one before.
I’m Rajesh Kumar, a DevOps, SRE, DevSecOps, Cloud, and Platform Engineering expert passionate about sharing practical knowledge, real-world experiences, and industry best practices. I have worked at Cotocus and regularly write about technology, travel, investing, health, product reviews, and digital marketing through my various platforms.
I publish technical articles at DevOps School, travel stories at Holiday Landmark, stock market insights at Stocks Mantra, health and fitness guidance at My Medic Plus, product reviews at TrueReviewNow, and SEO and digital marketing strategies at Wizbrand.
Find Trusted Cardiac Hospitals
Compare heart hospitals by city and services — all in one place.
Explore Hospitals
Permission boundaries deserve as much attention as the agent’s reasoning capability. In a production workflow, an agent that can read sensitive records and also execute actions creates a very different risk profile from a read-only assistant. Least-privilege tool access, separate permissions for reading and writing, approval gates for high-impact actions, and short-lived credentials should be part of the architecture rather than added later.